Thrombolex, Inc.
Quick facts
Phase 3 pipeline
- r-tPA · Cardiovascular
r-tPA is a recombinant tissue plasminogen activator that converts plasminogen to plasmin, breaking down fibrin clots to restore blood flow.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Thrombolex, Inc.
What is Thrombolex, Inc.'s pipeline?
Thrombolex, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include r-tPA.
Related
- Sector hub: All tracked pharma companies